Benign Breast Biopsy Diagnosis and Subsequent Risk of Breast Cancer
|
|
- Blanche Cameron
- 7 years ago
- Views:
Transcription
1 467 Benign Breast Biopsy Diagnosis and Subsequent Risk of Breast Cancer Erin L. Ashbeck, 1 Robert D. Rosenberg, 2 Patricia M. Stauber, 1 and Charles R. Key 3 1 Epidemiology and Cancer Prevention, Cancer Research and Treatment Center and Departments of 2 Radiology and 3 Pathology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico Abstract Background: We examine benign breast biopsy diagnoses as reported by community pathologists in New Mexico and investigate associations with future breast cancer development. Methods: Using data collected between 1992 and 2000 by the New Mexico Mammography Project and cancer data through 2003 from the New Mexico Tumor Registry, we calculated breast cancer rates following 14,602 benign breast biopsies for women ages 30 to 89 years. For comparison, we also calculated the breast cancer rate following 215,283 normal screening mammograms. Hazard ratios (HR) are presented. Results: We identified 480 subsequent breast cancer diagnoses among 14,602 women with benign breast biopsies and 4,402 breast cancer diagnoses among 215,283 women with mammograms assigned a negative or benign finding assessment. Histologic diagnoses in absence of atypia had an age-adjusted HR of 1.95 [95% confidence interval (95% CI), ]. Among low-risk histologic diagnoses, the strongest associations with subsequent breast cancer development included adenosis, apocrine metaplasia, calcifications, and ductal hyperplasia. Fibroadenoma, inflammation, and cysts did not exhibit an association with breast cancer development. Women with low-risk diagnoses and breast tissue characterized as fatty or with scattered densities had a HR of 2.09 (95% CI, ), whereas women with low-risk histologic diagnoses and dense breasts had a HR of 3.36 (95% CI, ). Conclusions: The observed breast cancer occurrence contributes to evidence of increased risk following benign biopsy. The risk associated with histologic diagnoses in absence of atypia was twice the risk experienced by women with normal mammogram evaluations and may be modified by breast density. (Cancer Epidemiol Biomarkers Prev 2007;16(3):467 72) Introduction Benign histologic diagnoses of breast biopsies are common and have been associated with future development of breast cancer. Various pathologies are classified as benign, and although the risk increase associated with atypical hyperplasia has been well established (1-6), more prevalent histologic diagnoses have not been as extensively evaluated. The Cancer Committee of the College of American Pathologists updated their 1985 Consensus statement in 1998, classifying ductal carcinoma in situ, lobular carcinoma in situ, and atypical hyperplasia as marked or moderate risk factors for future development of invasive breast cancer, whereas the remaining lesions were classified as either slight or non risk factors (7, 8). However, Wang et al. (9) reported a statistically significant increased risk associated with these lower category lesions from the National Surgical Adjuvant Breast and Bowel Project s Breast Cancer Prevention Trial. Hartmann et al. reported findings from the Mayo Clinic suggesting increased risk persisting for at least 25 years for women diagnosed with benign breast disease, in contrast to earlier findings (10, 11), although no increased risk was found specifically for women with no family history and nonproliferative findings (12). Commonly diagnosed histologic features include adenosis, apocrine metaplasia, calcifications, cysts, fibroadenomas, fibrocystic changes, fibroses, ductal hyperplasia, and inflammation. Although a few studies (1, 3, 13-21) have investigated Received 5/14/06; revised 12/6/06; accepted 12/19/06. Grant support: National Cancer Institute grant 5 U01 CA The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Requests for reprints: Robert D. Rosenberg, Department of Radiology, MSC , 1 University of New Mexico, Albuquerque, NM Phone: ; Fax: rrosenb@unm.edu Copyright D 2007 American Association for Cancer Research. doi: / epi some of these histologic diagnoses, the degree of risk association has not been as well established, and there is need to confirm the significance of these diagnoses when made by community pathologists. To address these questions, we examined clinical pathology reports collected in New Mexico for 14,602 women with benign breast diagnoses. After a median of 6.8 years of follow-up time, 480 women were diagnosed with breast cancer. We calculated breast cancer rates for women diagnosed with common histologic features and compared breast cancer risk for these women with women with no known breast biopsy experience and a normal mammogram. Materials and Methods Data Collection. Benign breast pathology reports were collected and abstracted as part of the New Mexico Mammography Project. The New Mexico Mammography Project is a member of the Breast Cancer Surveillance Consortium, a National Cancer Institute funded project created to evaluate the effectiveness of mammography screening (22). The benign breast data are linked with the New Mexico Tumor Registry to ascertain the subsequent occurrence of breast cancer. The New Mexico Tumor Registry is a statewide, population-based cancer registry and one of the National Cancer Institute funded Surveillance, Epidemiology, and End Results registries that provide estimates of cancer incidence, treatment, and survival and mortality rates. The project was reviewed and approved by the University of New Mexico Health Sciences Center Human Research Review Committee. New Mexico Tumor Registry staff abstracted pathology reports using Systematized Nomenclature of Human and Veterinary Medicine codes. We grouped morphologic terms into broader categories for the analysis. The atypical hyperplasia category includes both lobular and ductal forms. The adenosis category includes adenosis, fibrosing adenosis, and
2 468 Benign Breast Biopsy and Cancer Risk Table 1. Patient characteristics Women with high-risk histologic diagnoses, n = 532 (%) Women with low-risk histologic diagnoses, n = 14,070 (%) Women with negative/benign mammograms, n = 215,283 (%) Age, y (8) 2,474 (18) 23,391 (11) (32) 5,160 (37) 78,595 (37) (30) 3,274 (23) 50,892 (24) (18) 2,010 (14) 35,881 (17) (11) 986 (7) 21,222 (10) (3) 166 (1) 5,302 (2) Race/ethnicity American Indian 19 (4) 435 (3) 15,299 (7) Hispanic 165 (31) 4,193 (30) 65,614 (30) Non-Hispanic White 324 (61) 8,571 (61) 123,455 (57) Other 8 (2) 209 (1) 3,152 (1) Missing 16 (3) 662 (5) 7,763 (4) Breast density Fatty/scattered densities 119 (22) 3,171 (23) 83,074 (39) Dense 182 (34) 4,404 (31) 57,868 (27) Missing 231 (43) 6,495 (46) 74,341 (35) Family history of breast cancer No 328 (62) 8,023 (57) 146,894 (68) Yes 48 (9) 1,097 (8) 17,793 (8) Missing 156 (29) 4,950 (35) 50,596 (24) adenofibrosis. The cysts category includes cyst, epithelial inclusion cyst, apocrine cyst, and hemorrhagic cyst. The fibroses category includes fibrosis, scar, diabetic fibrous mastopathy, and radial scar. The ductal hyperplasia category includes intraductal hyperplasia, papillomatosis, and intraductal papilloma. The inflammation category includes inflammation not otherwise specified, acute inflammation, abscess, chronic inflammation, granulomatous inflammation, lipogranuloma, foreign body giant cell granuloma, granulation tissue, and inflammatory fat necrosis. Population and Biopsy Selection. Women residing in New Mexico, ages 30 to 89 years, with a benign breast biopsy in our database between 1992 and 2000 were selected for analysis. Women with a known history of breast cancer, mastectomy, or breast implants at the time of biopsy were excluded. Starting with a woman s first breast biopsy report in the database, we identified any subsequent breast biopsy that occurred within 90 days and repeated the process until the 90 days following the last biopsy were biopsy-free, thus combining the results of all biopsies that occurred over a short period. The purpose of combining biopsy results clustered in time is to capture the most complete diagnosis available. Women diagnosed with ductal carcinoma in situ or invasive breast cancer within 90 days were excluded because we are only interested in following women with an entirely benign diagnosis. Followup time begins to accumulate on the 91st day after the diagnosis is complete. For comparison, we identified women according to the same selection and exclusion criteria with a screening mammogram assigned a negative or benign finding assessment, with no recommendations for additional evaluation, and with a recommendation to return for routine screening. Women with a known history of breast biopsy, breast cancer, mastectomy, or breast implants at the time of the mammogram were excluded. Women diagnosed with ductal carcinoma in situ or invasive breast cancer within 90 days of the mammogram were excluded. Follow-up time begins to accumulate on the 91st day after the mammogram. Statistical Analysis. The outcome, breast cancer, was defined as either ductal carcinoma in situ or invasive cancer. Breast cancer rates were calculated for each of the histologic categories described previously. We generated Kaplan-Meier plots (SAS 8.2, LIFETEST procedure) to show the breast cancer accumulation for each histologic group. We used Cox regression (SAS 8.2, PHREG procedure) to generate breast cancer hazard ratios (HR), and the women with negative and benign finding mammograms served as a reference group. Women in the reference group were censored at the time of any subsequent benign biopsies. If a woman initially received a negative mammogram diagnosis and later received a benign biopsy diagnosis, then she is included in both the benign biopsy group and the negative mammogram group, with her follow-up time allocated accordingly. We had to consider that a single pathology report often lists multiple histologic features and calculated Pearson correlation coefficients to evaluate the association among histologic diagnoses. Because atypical hyperplasia, cytologic atypia, and lobular carcinoma in situ diagnoses are well documented in the literature in terms of their association with elevated risk, we separated any diagnosis that included one of these highrisk histologies and refer to the remaining as low-risk histologic diagnoses. Existing literature does not provide sufficient guidance for further hierarchical classification among the low-risk histologic diagnoses. Therefore, although the group of women classified as high risk are mutually exclusive of the women in the low-risk groups, we did not use a hierarchical classification scheme for the low-risk diagnoses, and the specific low-risk groups are not mutually exclusive of each other. For example, if a woman has an initial diagnosis, including both adenosis and calcifications, she is included in the rates and HRs for adenosis and for calcifications. However, if her initial diagnosis also includes atypical hyperplasia, she is classified as high risk and only included in the analysis for atypical hyperplasia and not in the analyses of adenosis or calcifications. Each diagnosis group was examined individually; for example, in the analysis of adenosis, women with a low-risk diagnosis that includes adenosis were compared with women with a negative/benign mammogram in a Cox model. The first HR in Table 3 is adjusted for age in deciles. The second HR is further adjusted by including indicator variables for concurrent diagnoses of apocrine metaplasia, calcifications, cysts, fibroadenoma, fibroses, ductal hyperplasia, and inflammation. Analyses of other specific low-risk diagnoses are similarly adjusted for concurrent low-risk diagnoses. We investigated breast density, approximate menopausal status, and family history of breast cancer as modifiers of the association between benign histologic diagnoses and future
3 Cancer Epidemiology, Biomarkers & Prevention 469 Table 2. Breast cancer rates following benign biopsy Breast cancers (in situ/invasive) Women at risk Breast cancers per 100,000 woman-years Negative/benign mammograms 4,402 (710:3,692) 215, Atypical hyperplasia 17 (5:12) 319 1,148 Cytologic atypia 4 (1:3) Lobular carcinoma in situ 8 (4:4) Low-risk histologic diagnoses 451 (82:369) 14, Adenosis 36 (8:28) 1, Apocrine metaplasia 45 (5:40) 1, Calcifications 67 (13:54) 2, Cysts 25 (4:21) 1, Fibroadenoma 54 (11:43) 2, Fibrocystic breast changes 217 (48:169) 6, Fibroses 68 (11:57) 2, Hyperplasia, ductal 74 (15:59) 2, Inflammation 18 (10:8) 1, breast cancer development and also adjusted for these factors, age and race/ethnicity, as potential confounders when possible, depending on the availability of data. Results Benign breast biopsies were identified for 14,602 women, and screening mammograms with a negative or benign finding assessment were identified for 215,283 women. Eighty-five percent of the pathology reports resulted from surgical biopsies, predominantly excisional and core biopsies, whereas the remaining 15% of the pathology reports were from fineneedle aspirations. Five hundred thirty-two of the 14,602 women with benign breast biopsies received a high-risk diagnosis. Among the women with benign breast biopsies, 93% had only one biopsy to consider, whereas 6.2% had two biopsies in a short period, and 0.4% had three or four biopsies in the diagnostic series. The maximum duration from first to last biopsy in the diagnostic series was 145 days. Baseline characteristics, including age, race/ethnicity, breast density, and family history of breast cancer in a first-degree relative, are presented in Table 1, stratified into three groups, including women with high-risk histologic diagnoses, women with low-risk histologic diagnoses, and women with screening mammograms assigned a negative or benign finding assessment. The age distributions among the three groups were similar, although women with high-risk histologic diagnoses were slightly older. Although the racial/ethnic distributions were also similar among the three groups, Non-Hispanic White women had a higher representation in the benign biopsy groups compared with the negative mammogram group. Despite considerable missing data for breast density (from 35-46%), the available data suggest highest breast density among women with high-risk histologic diagnoses followed by women with low-risk histologic diagnoses and the lowest breast density among the negative mammogram group. We also see a slightly higher proportion of women with a family history of breast cancer among women with high-risk histologic diagnoses, although the availability of data was limited (24-35% missing). The pathology diagnosis was characterized by a single histologic category for 45% of the women, whereas the remaining 55% was characterized by two or more histologic categories. Calcifications exhibited the strongest correlation with other histologic categories, including ductal hyperplasia (0.22), adenosis (0.20), atypical hyperplasia (0.16), and fibrocystic changes (0.16). Fibrocystic changes were positively correlated with ductal hyperplasia (0.15) and calcifications (0.16). Apocrine metaplasia was also correlated with hyperplasia, not otherwise specified (0.15), and ductal hyperplasia was correlated with adenosis (0.14). The strongest negative correlations include fibrocystic changes with fibroadenoma ( 0.15), Figure 1. Cumulative incidence of breast cancer following benign breast diagnosis.
4 470 Benign Breast Biopsy and Cancer Risk Figure 2. Cumulative incidence of breast cancer following low-risk histologic diagnosis. fibroses ( 0.14), inconclusive ( 0.13), negative ( 0.21), and other ( 0.13). Negative results were also negatively correlated with fibroadenomas ( 0.15). The absolute value of the correlation coefficient between all other pairs of histologic categories was V0.11 and in most cases <0.06. Among the 215,283 women with negative mammograms, 6,300 women eventually had a breast biopsy with a benign diagnosis, at which time they were censored and then contributed to the 14,602 women with benign breast biopsies, with their remaining follow-up time allocated accordingly. Among the 14,602 women with benign breast biopsies, 2,021 women eventually had a subsequent breast biopsy with a benign diagnosis; we did not consider these subsequent diagnoses in our analysis. The median observed time at risk following negative mammograms and benign breast biopsies was 2,920 and 2,491 days, respectively. We identified 480 breast cancer diagnoses among the women with benign breast biopsies and 4,402 breast cancer diagnoses among the women with negative mammograms. The counts of in situ and invasive cancers are listed in Table 2. The breast cancer rates for women who were diagnosed with atypical hyperplasia, cytologic atypia, and lobular carcinoma in situ were 1,148 per 100,000 woman-years, 770 per 100,000 woman-years, and 899 per 100,000 woman-years, respectively. The remaining women with low-risk histologic diagnoses had a breast cancer rate of 466 per 100,000 woman-years, whereas the women who received negative or benign finding assessments for their screening mammograms had a breast cancer rate of 266 per 100,000 woman-years (Table 2). Specific lowrisk histologic diagnoses followed by the highest breast cancer rates were adenosis, apocrine metaplasia, calcifications, and hyperplasia. Fibroadenomas and inflammation had the lowest subsequent breast cancer rates. Figure 1 shows the unadjusted cumulative incidence of breast cancer events among women with high- and low-risk benign breast diagnoses and women with normal mammogram results. Breast cancer incidence following low-risk diagnoses seems steady during the course of the study period and is consistently between the breast cancer incidence experienced by the group of women diagnosed with high-risk diagnoses and the group of women with normal mammograms. There is no sudden increase in cancer incidence following benign diagnosis to suggest that the subsequent risk is due to missed cancer. Table 3. Breast cancer HRs following benign biopsy HR* HR*,c adjusted for other low-risk diagnoses HR*, c,b adjusted for breast density, ethnicity, and family history Negative/benign 1.00 x 1.00 x 1.00 x mammograms Atypical hyperplasia 4.40 ( ) 5.80 ( ) Cytologic atypia 3.58 ( ) 3.40 ( ) Lobular carcinoma in situ 3.20 ( ) 2.09 ( ) Low-risk histologic diagnoses 1.95 ( ) 1.75 ( ) Adenosis 2.28 ( ) 2.72 ( ) 2.81 ( ) Apocrine Metaplasia 3.05 ( ) 3.26 ( ) 3.89 ( ) Calcifications 2.27 ( ) 2.07 ( ) 2.14 ( ) Cysts 1.64 ( ) 1.28 ( ) 1.37 ( ) Fibroadenoma 1.28 ( ) 1.14 ( ) 1.01 ( ) Fibroses 1.94 ( ) 1.81 ( ) 1.61 ( ) Hyperplasia, ductal 2.13 ( ) 2.18 ( ) 1.93 ( ) Inflammation 1.35 ( ) 1.11 ( ) 1.71 ( ) *HRs (95% CI) are adjusted for age in deciles. chrs for specific low-risk diagnoses are adjusted for concurrent low-risk diagnoses seen in this list. bhrs adjusted for breast density, ethnicity, and family history of breast cancer are calculated from a subset of women with available data for all of these variables. xwomen with negative/benign mammograms are the reference group in all models.
5 Cancer Epidemiology, Biomarkers & Prevention 471 Table 4. Breast cancer HRs following benign biopsy, stratified by approximate menopausal status and breast density HRs*,c stratified by approximate menopausal status HRs*,c stratified by breast density b Age V55 y Age >55 y Fatty/scattered densities Dense Negative/benign mammograms 1.00 x 1.16 ( ) 1.00 k 2.02 ( ) Low-risk histologic diagnoses 1.87 ( ) 2.39 ( ) 2.09 ( ) 3.36 ( ) Adenosis 2.51 ( ) 3.53 ( ) 4.28 ( ) 4.63 ( ) Apocrine metaplasia 3.36 ( ) 3.68 ( ) 4.38 ( ) 7.58 ( ) Calcifications 2.16 ( ) 2.31 ( ) 3.15 ( ) 3.12 ( ) Cysts 1.16 ( ) 1.70 ( ) 0.38 ( ) 3.26 ( ) Fibroadenoma 1.23 ( ) 1.09 ( ) 1.49 ( ) 1.58 ( ) Fibroses 1.52 ( ) 2.45 ( ) 1.78 ( ) 3.10 ( ) Hyperplasia, Ductal 2.13 ( ) 2.58 ( ) 2.36 ( ) 3.86 ( ) Inflammation 1.09 ( ) 1.39 ( ) 1.90 ( ) 3.16 ( ) *HRs (95% CI) are adjusted for age in deciles. chrs for specific low-risk diagnoses are adjusted for concurrent low-risk diagnoses seen in this list. bhrs stratified by breast density are calculated from a subset of women with available breast density scores. xwomen with negative/benign mammograms ages V55 y are the reference group in all models stratified by approximate menopausal status. kwomen with negative/benign mammograms with fatty/scattered breast densities are the reference group in all models stratified by breast density. Figure 2 examines the low-risk histology diagnoses individually over time. We only display curves for groups with larger sample sizes and restrict our interpretation to the first several years, as the curves become erratic due to limited sample size after 4 to 5 years. Women diagnosed with apocrine metaplasia, adenosis, calcifications, ductal hyperplasia, fibroses, and cysts experienced more breast cancer diagnoses than those with normal mammograms. Women diagnosed with inflammation and fibroadenomas did not experience more breast cancer diagnoses than women with normal mammograms. The age-adjusted HRs and 95% confidence intervals (95% CI) for atypical hyperplasia, cytologic atypia, and lobular carcinoma in situ were 4.40 ( ), 3.58 ( ), and 3.20 ( ), respectively, compared with women with screening mammograms with negative or benign finding assessments (Table 3). The remaining low-risk histologic diagnoses had an age-adjusted HR of 1.95 (95% CI, ). The term fibrocystic breast changes was broadly applied by clinical pathologists, as 44% of the low-risk diagnoses included a similar term (6,128 women with fibrocystic breast changes of the 14,070 women with low-risk diagnoses; Table 2), either alone or in conjunction with other descriptors, with an ageadjusted HR of 2.07 (95% CI, ). Specific low-risk histologic diagnoses with the strongest associations with subsequent breast cancer development included adenosis, apocrine metaplasia, calcifications, and ductal hyperplasia (Table 3). After adjustment for concurrent low-risk diagnoses, the HRs increased for adenosis, apocrine metaplasia, and ductal hyperplasia, whereas they decreased for other low-risk diagnoses. Cysts were significantly associated with subsequent breast cancer development before adjustment for concurrent diagnoses with HR of 1.64 (95% CI, ), whereas after adjustment, the HR attenuated and was no longer significant with a HR of 1.28 (95% CI, ). Fibroadenoma and inflammation diagnoses did not exhibit a notable magnitude of effect or a statistically significant association with subsequent breast cancer development. When we stratified the data at age 55 years as an approximation for menopausal status, the HRs were consistently higher in the group presumed to be postmenopausal (Table 4). Women with a low-risk histologic diagnosis who were <55 years of age had a HR of 1.87 (95% CI, ) compared with women 55 years or older with HR of 2.39 (95% CI, ). Because facility participation with the New Mexico Mammography Project is voluntary and facilities use widely varying data systems and patient forms, missing data for race/ethnicity, breast density, and family history of breast cancer limited our ability to evaluate interactions and confounders. The extent of missing data is noted in Table 1. After limiting the analysis to patients with available data, we adjusted HRs for age, race/ethnicity, breast density, and family history of breast cancer, as well as concurrent diagnoses in specific low-risk categories (Table 3). We stratified by family history of breast cancer and found that women with low-risk diagnoses and a family history of breast cancer had an age-adjusted HR of 2.33 (95% CI, ), whereas women with a low-risk diagnosis and no family history of breast cancer had an age-adjusted HR of 2.14 (95% CI, ). The number of women with a family history of breast cancer is inadequate for further analyses of possible risk modification in the specific low-risk categories. We stratified according to breast density (Table 4) and found that women with low-risk histologic diagnoses and breast tissue characterized as fatty or with scattered densities had a HR of 2.09 (95% CI, ), whereas women with low-risk histologic diagnoses and dense breast tissue had a HR of 3.36 (95% CI, ). Discussion The observed breast cancer rates and HRs further contribute to evidence of an increase in breast cancer risk following benign biopsy, including some histologic diagnoses in absence of atypia. Atypical hyperplasia, cytologic atypia, and lobular carcinoma in situ were associated with an elevated breast cancer risk that is consistent with other published data. As a group, the more common low-risk histologic diagnoses showed a statistically significant association with subsequent breast cancer development, with a risk increase almost twice the risk experienced by women with normal mammogram evaluations. A few of the broad diagnosis categories were found to have stronger associations with subsequent breast cancer development, including adenosis, apocrine metaplasia, calcifications, and ductal hyperplasia. Fibroadenomas, inflammation, and cysts did not show an association with subsequent breast cancer development. Although fibrocystic disease has been repeatedly referred to as term lacking in clinical meaning (7, 8, 23), the terms fibrocystic disease and fibrocystic changes were widely used by clinical pathologists in New Mexico. This term did not provide further distinction about subsequent risk. Evidence that breast density is associated with the risk of breast cancer has been reported elsewhere (24-28). Our data suggest that breast density modifies the risk associated with low-risk histologic diagnosis. Family history of breast cancer
6 472 Benign Breast Biopsy and Cancer Risk slightly modified the association between low-risk histologic diagnosis and breast cancer development in our data, though the extent of missing data limits our ability to evaluate interactions. The results of these analyses must be considered in the context of several limitations. We did not attempt to distinguish between markers of elevated overall breast cancer risk and lesions with increased risk of local breast cancer occurrence. We did not have complete information about all of the known epidemiologic breast cancer risk factors available for evaluating potential confounders and effect modifiers, as we could not dictate what information was collected by the facilities. The histologic terms were abstracted from clinical pathology reports, meaning each diagnosis was not the result of a consistent team of pathologists working with strictly defined criteria and an algorithm to resolve disagreements, as used in other studies. Furthermore, poor agreement among pathologists about the distinction between low-grade ductal carcinoma in situ and atypical ductal hyperplasia in the absence of a strictly controlled protocol has been discussed elsewhere (29-31). Pathologists also differ in the level of detail they specify on a clinical report, and some may report only the primary histologic feature, whereas others may report multiple features. Whereas some investigators have chosen to compare with the overall population (12), we used women with a normal mammogram as our reference population. Women receiving regular health care, such as mammography or benign breast biopsies, will have a higher chance of cancer diagnosis than those not receiving regular health care. Clearly, the choice of control group could alter the HR estimates. Physicians who make decisions about patient care and advise patients about the importance of any pathology diagnosis do so based on clinical pathology reports. Although this analysis does not constitute biological evidence of the risk of a particular histologic feature, this analysis is useful as it evaluates the association between actual information provided to practicing physicians and subsequent breast cancer diagnosis. Acknowledgments We thank William C. Hunt and Deirdre Hill for helpful comments on an earlier version of this manuscript. References 1. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985;312: Page DL, Dupont WD, Rogers LW, Rados MS. Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer 1985;55: Carter CL, Dorle DK, Micozzi MS, Schatzkin A, Taylor PR. A prospective study of the development of breast cancer in 16,692 women with benign breast disease. Am J Epidemiol 1988;128: Marshall LM, Hunter DJ, Connolly JL, et al. Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types. Cancer Epidemiol Biomarkers Prev 1997;6: London SJ, Connolly JL, Schnitt SJ, Colditz GA. A prospective study of benign breast disease and the risk of breast cancer. JAMA 1992;267: Page DL, Schuyler PA, Dupont WD, Jensen RA, Plummer WD, Jr., Simpson JF. Aypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study. Lancet 2003;361: Hutter RVP. Consensus meeting: is fibrocystic disease of the breast precancerous? Arch Pathol Lab Med 1986;110: Fitzgibbons PL, Henson DE, Hutter RVP. Benign breast changes and the risk for subsequent breast cancer. Arch Pathol Lab Med 1998;122: Wang J, Costantino JP, Tan-Chiu E, Wickerham DL, Paik S, Wolmark N. Lower-category benign breast disease and the risk of invasive breast cancer. J Natl Cancer Inst 2004;96: Dupont WD, Page DL. Relative risk of breast cancer varies with time since diagnosis of atypical hyperplasia. Hum Pathol 1989;20: Krieger N, Hiatt RA. Risk of breast cancer after benign breast diseases. Variation by histologic type, degree of atypia, age at biopsy, and length of follow-up. Am J Epidemiol 1992;135: Hartmann LC, Sellers TA, Frost MH, et al. Benign breast disease and the risk of breast cancer. N Engl J Med 2005;353: Shaaban AM, Sloane JP, West CR, et al. Histopathologic type of benign breast lesions and the risk of breast cancer: case-control study. Am J Surg Pathol 2002;26: Jensen RA, Page DL, Dupont WD, Rogers LW. Invasive breast cancer risk in women with sclerosing adenosis. Cancer 1989;64: Seidman JD, Ashton M, Lefkowitz M. Atypical apocrine adenosis of the breast: a clinicopathologic study of 37 patients with 8.7-year follow-up. Cancer 1996;77: Rosenfeld I, Tartter PI, Gajdos C, Hermann G, Bleiweiss I. The significance of malignancies incidental to microcalcifications in breast spot localization biopsy specimens. Am J Surg 2001;182: Dupont WD, Page DL, Parl FF, et al. Long-term risk of breast cancer in women with fibroadenoma. N Engl J Med 1994;331: Jacobs TW, Byrne C, Colditz G, Connolly JL, Schnitt SJ. Radial scars in benign breast-biopsy specimens and the risk of breast cancer. N Engl J Med 1999;340: King TA, Scharfenberg JC, Smetherman DH, Farkas EA, Bolton JS, Fuhrman GM. A Better understanding of the term radial scar. Am J Surg 2000;180: Sanders ME, Dupont WD, Schuyler PA, Simpson JF, Page DL. Interdependence of radial scar and proliferative disease with respect to invasive breast cancer risk in benign breast biopsies. Mod Pathol 2002;15: Patterson JA, Scott M, Anderson N, Kirk SJ. Radial scar, complex sclerosing lesion, and risk of breast cancer. Analysis of 175 cases in Northern Ireland. Eur J Surg Oncol 2004;30: Ballard-Barbash R, Taplin SH, Yankaskas BC, et al. Breast Cancer Surveillance Consortium: a national mammography screening and outcomes database. Am J Roentgenol 1997;169: Schnitt SJ. Benign breast disease and breast cancer risk: morphology and beyond. Am J Surg Pathol 2003;27: Saftlas AF, Szklo M. Mammographic parenchymal patterns and breast cancer risk. Epidemiol Rev 1987;9: Oza AM, Boyd NF. Mammographic parenchymal patterns: a marker of breast cancer risk. Epidemiol Rev 1993;15: Boyd NF, Lockwood GA, Byng JW, Tritchler DL, Yaffe MJ. Mammographic densities and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1998;12: Boyd NF, Jensen HM, Cooke G, Lee Han H, Lockwood GA, Miller A; Reference Pathologists of the Canadian National Breast Screening Study. Mammographic densities and the prevalence and incidence of histological types of benign breast disease. Eur J Cancer Prev 2000;9: Ursin G, Hovanessian-Larsen L, Parisky YR, Pike MC, Wu AH. Greatly increased occurrence of breast cancers in areas of mammographically dense tissue. Breast Cancer Res 2005;7:R Rosai J. Borderline epithelial lesions of the breast. Am J Surg Path 1991;15: Bodian CA, Perzin KH, Lattes R, et al. Reproducibility and validity of pathologic classifications of benign breast disease and implications for clinical applications. Cancer 1993;71: Schnitt SJ, Connolly JL, Tavassoli FA, et al. Interobserver reproducibility in the diagnosis of ductal proliferative breast lesions using standardized criteria. Am J Surg Pathol 1992;16:
Nicole Kounalakis, MD
Breast Disease: Diagnosis and Management Nicole Kounalakis, MD Assistant Professor of Surgery Goal of Breast Evaluation The goal of breast evaluation is to classify findings as: normal physiologic variations
More informationHow To Decide If You Should Get A Mammogram
American Medical Women s Association Position Paper on Principals of Breast Cancer Screening Breast cancer affects one woman in eight in the United States and is the most common cancer diagnosed in women
More informationWisconsin Cancer Data Bulletin Wisconsin Department of Health Services Division of Public Health Office of Health Informatics
Wisconsin Cancer Data Bulletin Wisconsin Department of Health Services Division of Public Health Office of Health Informatics In Situ Breast Cancer in Wisconsin INTRODUCTION This bulletin provides information
More informationEvaluation and Management of the Breast Mass. Gary Dunnington,, M.D. Department of Surgery Internal Medicine Ambulatory Conference December 4, 2003
Evaluation and Management of the Breast Mass Gary Dunnington,, M.D. Department of Surgery Internal Medicine Ambulatory Conference December 4, 2003 Common Presentations of Breast Disease Breast Mass Abnormal
More informationBreast Imaging Made Brief and Simple. Jane Clayton MD Associate Professor Department of Radiology LSUHSC New Orleans, LA
Breast Imaging Made Brief and Simple Jane Clayton MD Associate Professor Department of Radiology LSUHSC New Orleans, LA What women are referred for breast imaging? Two groups of women are referred for
More informationMAMMOGRAPHY GOALS AND OBJECTIVES
MAMMOGRAPHY GOALS AND OBJECTIVES GOALS: After completion of the mammography rotations, the resident will be able to: 1. Demonstrate learning of the knowledge-based objectives-(practice Base Learning) 2.
More informationVariability and Accuracy in Mammographic Interpretation Using the American College of Radiology Breast Imaging Reporting and Data System
Variability and Accuracy in Mammographic Interpretation Using the American College of Radiology Breast Imaging Reporting and Data System Karla Kerlikowske, Deborah Grady, John Barclay, Steven D. Frankel,
More informationMammography Education, Inc.
Mammography Education, Inc. 2011 LÁSZLÓ TABÁR, M.D.,F.A.C.R (Hon) 3D image of a milk duct MULTIMODALITY DETECTION and DIAGNOSIS of BREAST DISEASES PRAGUE, Czech Republic Crown Plaza, Prague June 29 - July
More informationNon-cancerous Breast Conditions
Non-cancerous Breast Conditions Non-cancerous breast conditions are very common and most women have them. In fact, most breast changes that are tested turn out to be benign. Benign is another word for
More informationEffect of Risk and Prognosis Factors on Breast Cancer Survival: Study of a Large Dataset with a Long Term Follow-up
Georgia State University ScholarWorks @ Georgia State University Mathematics Theses Department of Mathematics and Statistics 7-28-2012 Effect of Risk and Prognosis Factors on Breast Cancer Survival: Study
More informationScreening Mammography for Breast Cancer: American College of Preventive Medicine Practice Policy Statement
Screening Mammography for Breast Cancer: American College of Preventive Medicine Practice Policy Statement Rebecca Ferrini, MD, Elizabeth Mannino, MD, Edith Ramsdell, MD and Linda Hill, MD, MPH Burden
More informationSustaining a High-Quality Breast MRI Practice
Sustaining a High-Quality Breast MRI Practice Christoph Lee, MD, MSHS Associate Professor of Radiology Adjunct Associate Professor, Health Services University of Washington September 11, 2015 Overview
More informationLocal control in ductal carcinoma in situ treated by excision alone: incremental benefit of larger margins
The American Journal of Surgery 190 (2005) 521 525 George Peter s Award Winner Local control in ductal carcinoma in situ treated by excision alone: incremental benefit of larger margins Heather R. MacDonald,
More informationBreast cancer close to the nipple: Does this carry a higher risk ofaxillary node metastasesupon diagnosis?
Breast cancer close to the nipple: Does this carry a higher risk ofaxillary node metastasesupon diagnosis? Erin I. Lewis, BUSM 2010 Cheri Nguyen, BUSM 2008 Priscilla Slanetz, M.D., MPH Al Ozonoff, Ph.d.
More informationKomorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group
Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Lotte Holm Land MD, ph.d. Onkologisk Afd. R. OUH Kræft og komorbiditet - alle skal
More informationBreast Ultrasound: Benign vs. Malignant Lesions
October 25-November 19, 2004 Breast Ultrasound: Benign vs. Malignant Lesions Jill Steinkeler,, Tufts University School of Medicine IV Breast Anatomy Case Presentation-Patient 1 62 year old woman with a
More informationBREAST IMAGING. Developed by the Ad Hoc Committee on Resident and Fellow Education of the Society of Breast Imaging
BREAST IMAGING Developed by the Ad Hoc Committee on Resident and Fellow Education of the Society of Breast Imaging Stephen A. Feig, M.D., Chair Ferris Hall, M.D. Debra Ikeda, M.D. Ellen Mendelson, M.D.
More informationBreast Cancer: from bedside and grossing room to diagnoses and beyond. Adriana Corben, M.D.
Breast Cancer: from bedside and grossing room to diagnoses and beyond Adriana Corben, M.D. About breast anatomy Breasts are special organs that develop in women during puberty when female hormones are
More informationD. FREQUENTLY ASKED QUESTIONS
ACR BI-RADS ATLAS D. FREQUENTLY ASKED QUESTIONS 1. Under MQSA, is it necessary to include a numeric assessment code (i.e., 0, 1, 2, 3, 4, 5, or 6) in addition to the assessment category in all mammography
More informationEpidemiology. Breast Cancer Screening, Diagnosis, Biology and Long-Term Follow-Up EDUCATIONAL OBJECTIVES
Cancer Treatment Centers of America Breast Cancer: Screening, Diagnosis, Biology and Long-Term Follow-Up Presented to: Atlantic Regional Osteopathic Conference Presented by: Pamela Crilley, DO Date: April
More informationBreast Cancer Among the US Male Population June 2015
Breast Cancer Among the US Male Population June 2015 Centers for Disease Control and Prevention NCCDPHP, DCPC, Cancer Surveillance Branch Background Focus on female breast cancer Few studies on male breast
More informationChanges in Breast Cancer Reports After Second Opinion. Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain
Changes in Breast Cancer Reports After Second Opinion Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain Second Opinion in Breast Pathology Usually requested when a patient is referred
More informationVI. FREQUENTLY ASKED QUESTIONS CONCERNING BREAST IMAGING AUDITS
ACR BI-RADS ATLAS VI. FREQUENTLY ASKED QUESTIONS CONCERNING BREAST IMAGING AUDITS American College of Radiology 55 ACR BI-RADS ATLAS A. All Breast Imaging Modalities 1. According to the BI-RADS Atlas,
More informationDuctal carcinoma in situ (DCIS)
DIAGNOSIS: DCIS Ductal carcinoma in situ (DCIS) This factsheet gives information on an early form of breast cancer called ductal carcinoma in situ (DCIS). It explains what it is, how your breast is made
More informationBreast Fine Needle Aspiration Cytology Reporting : A Study of Application of Probabilistic Approach
54 Original Study Indian Medical Gazette FEBRUARY 2013 Breast Fine Needle Aspiration Cytology Reporting : A Study of Application of Probabilistic Approach Amrish N. Pandya, Professor & Head, IHBT Department,
More informationInformation Model Requirements of Post-Coordinated SNOMED CT Expressions for Structured Pathology Reports
Information Model Requirements of Post-Coordinated SNOMED CT Expressions for Structured Pathology Reports W. Scott Campbell, Ph.D., MBA James R. Campbell, MD Acknowledgements Steven H. Hinrichs, MD Chairman
More informationExamples of good screening tests include: mammography for breast cancer screening and Pap smears for cervical cancer screening.
CANCER SCREENING Dr. Tracy Sexton (updated July 2010) What is screening? Screening is the identification of asymptomatic disease or risk factors by history taking, physical examination, laboratory tests
More informationOffice of Population Health Genomics
Office of Population Health Genomics Policy: Protocol for the management of female BRCA mutation carriers in Western Australia Purpose: Best Practice guidelines for the management of female BRCA mutation
More informationOBJECTIVES By the end of this segment, the community participant will be able to:
Cancer 101: Cancer Diagnosis and Staging Linda U. Krebs, RN, PhD, AOCN, FAAN OCEAN Native Navigators and the Cancer Continuum (NNACC) (NCMHD R24MD002811) Cancer 101: Diagnosis & Staging (Watanabe-Galloway
More informationCHILDHOOD CANCER SURVIVOR STUDY Analysis Concept Proposal
CHILDHOOD CANCER SURVIVOR STUDY Analysis Concept Proposal 1. STUDY TITLE: Longitudinal Assessment of Chronic Health Conditions: The Aging of Childhood Cancer Survivors 2. WORKING GROUP AND INVESTIGATORS:
More informationA Guide to Breast Imaging: The Latest Technology for Screening and Detecting Breast Cancer
A Guide to Breast Imaging: The Latest Technology for Screening and Detecting Breast Cancer Sally Herschorn, MD Associate Professor of Radiology University of Vermont College of Medicine Medical Director
More informationHAVE YOU BEEN NEWLY DIAGNOSED with DCIS?
HAVE YOU BEEN NEWLY DIAGNOSED with DCIS? Jen D. Mother and volunteer. Diagnosed with DCIS breast cancer in 2012. An educational guide prepared by Genomic Health This guide is designed to educate women
More informationGuideline for the Imaging of Patients Presenting with Breast Symptoms incorporating the guideline for the use of MRI in breast cancer
Guideline for the Imaging of Patients Presenting with Breast Symptoms incorporating the guideline for the use of MRI in breast cancer Version History Version Date Summary of Change/Process 0.1 09.01.11
More informationBreast Density Legislation: Implications for primary care providers
Breast Density Legislation: Implications for primary care providers Deborah J. Rhodes MD Associate Professor of Medicine 2012 MFMER slide-1 Disclosure Relevant financial relationship(s) None Off-label
More informationInfrared Thermography Not a Useful Breast Cancer Screening Tool
Contact: Jeanne-Marie Phillips Sharon Grutman HealthFlash Marketing The American Society of Breast Surgeons 203-977-3333 877-992-5470 Infrared Thermography Not a Useful Breast Cancer Screening Tool Mammography
More informationPolyps. Hyperplasias. CAP 2011: Course AP104. The High Risk Benign Endometrium. Mutter and Nucci 1
Course AP104 Endometrial Hyperplasia A morphologic Definition Hyperplasias Hormonal Effect or Precancer? George L. Mutter, MD Harvard Medical School and Brigham and Women s Hospital Boston, MA Endometrial
More informationElectronic health records to study population health: opportunities and challenges
Electronic health records to study population health: opportunities and challenges Caroline A. Thompson, PhD, MPH Assistant Professor of Epidemiology San Diego State University Caroline.Thompson@mail.sdsu.edu
More informationMeasure #405: Appropriate Follow-up Imaging for Incidental Abdominal Lesions National Quality Strategy Domain: Effective Clinical Care
Measure #405: Appropriate Follow-up Imaging for Incidental Abdominal Lesions National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY DESCRIPTION:
More informationTemporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008
Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,
More informationUse of the American College of Radiology BI-RADS to Report on the Mammographic Evaluation of Women with Signs and Symptoms of Breast Disease 1
Berta M. Geller, EdD William E. Barlow, PhD Rachel Ballard-Barbash, MD, MPH Virginia L. Ernster, PhD Bonnie C. Yankaskas, PhD Edward A. Sickles, MD Patricia A. Carney, PhD Mark B. Dignan, PhD Robert D.
More informationProvider Reimbursement for Women's Cancer Screening Program
Reimbursement Schedule July 1, 2015 June 30, 2016 Office Visits - Established Patients Office Visit / Minimal / no physician 99211 $ 16.70 Office Visit / Problem focused History / exam 99212 $ 36.46 Preventive
More informationThe effects of hormone replacement therapy on postmenopausal breast cancer biology and survival
The American Journal of Surgery (2009) 197, 403 407 The Midwest Surgical Association The effects of hormone replacement therapy on postmenopausal breast cancer biology and survival Stephen F. Sener, M.D.*,
More informationCase-control studies. Alfredo Morabia
Case-control studies Alfredo Morabia Division d épidémiologie Clinique, Département de médecine communautaire, HUG Alfredo.Morabia@hcuge.ch www.epidemiologie.ch Outline Case-control study Relation to cohort
More informationRotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma
Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma Medical Expert: Breast Rotation Specific Competencies/Objectives 1.0 Medical History
More informationPatologia neoplastica borderline della mammella"
Patologia neoplastica borderline della mammella" Anna Sapino Department of Medical Sciences University of Torino (Italy) B3 Lesion of uncertain malignant potential This category mainly consists of lesions
More information4/8/13. Pre-test Audience Response. Prostate Cancer 2012. Screening and Treatment of Prostate Cancer: The 2013 Perspective
Pre-test Audience Response Screening and Treatment of Prostate Cancer: The 2013 Perspective 1. I do not offer routine PSA screening, and the USPSTF D recommendation will not change my practice. 2. In light
More information2. Incidence, prevalence and duration of breastfeeding
2. Incidence, prevalence and duration of breastfeeding Key Findings Mothers in the UK are breastfeeding their babies for longer with one in three mothers still breastfeeding at six months in 2010 compared
More informationPSA Testing 101. Stanley H. Weiss, MD. Professor, UMDNJ-New Jersey Medical School. Director & PI, Essex County Cancer Coalition. weiss@umdnj.
PSA Testing 101 Stanley H. Weiss, MD Professor, UMDNJ-New Jersey Medical School Director & PI, Essex County Cancer Coalition weiss@umdnj.edu September 23, 2010 Screening: 3 tests for PCa A good screening
More informationUnderstanding. Breast Changes. National Cancer Institute. A Health Guide for Women. National Institutes of Health
National Cancer Institute Understanding Breast Changes A Health Guide for Women U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health It was easier to talk with my doctor after reading
More informationHarlem Hospital Center Integrated Radiology Residency Program Mammography Educational goals and objectives
Harlem Hospital Center Integrated Radiology Residency Program Mammography Educational goals and objectives Rotation 1 (Radiology year 1/2) Knowledge Based Objectives: At the end of the rotation, the resident
More informationBREAST CANCER RISK ASSESSMENT AND PRIMARY PREVENTION FOR HIGH RISK PATIENTS, RACHEL CATHERINE JANKOWITZ, MD 1
FOR HIGH RISK PATIENTS, RACHEL CATHERINE JANKOWITZ, MD 1 Hello, my name is Rachel Jankowitz, I m an assistant professor of medicine in the Division of Hematology Oncology at the University of Pittsburgh
More informationPART TWO: DIAGNOSING BREAST CANCER
PART TWO: DIAGNOSING BREAST CANCER What is Breast Cancer? Normal cells can turn into cancer because of genetic inheritance or repeated exposure to a cancer-related substance in the environment, such as
More informationNew Brunswick Breast Cancer Screening Services
New Brunswick Breast Cancer Screening Services Report on Program Performance 1996-2009 Message from the New Brunswick Cancer Network (NBCN) Co-CEOs The New Brunswick Cancer Network is pleased to provide
More informationSupplementary Online Content
Supplementary Online Content Harshman, LC, Wang X, Nakabayashi M, et al. Statin use at the time of initiation of androgen deprivation therapy and time to progression in patients with hormone-sensitive
More informationHologic Selenia Dimensions C-View Software Module. October 24, 2012
Hologic Selenia Dimensions C-View Software Module October 24, 2012 Introduction and Agenda Peter Soltani, Ph.D. Senior VP & GM, Breast Health Hologic, Inc. Agenda Technology Overview Clinical Overview
More informationDuctal Carcinoma In Situ Treated With Breast-Conserving Surgery and Radiotherapy: A Comparison With ECOG Study 5194
Ductal Carcinoma In Situ Treated With Breast-Conserving Surgery and Radiotherapy: A Comparison With ECOG Study 5194 Sabin B. Motwani, MD 1 ; Sharad Goyal, MD 1 ; Meena S. Moran, MD 2 ; Arpit Chhabra, BS
More informationKIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA
KIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA O.E. Stakhvoskyi, E.O. Stakhovsky, Y.V. Vitruk, O.A. Voylenko, P.S. Vukalovich, V.A. Kotov, O.M. Gavriluk National Canсer Institute,
More informationPopulations of Color in Minnesota
Populations of Color in Minnesota Health Status Report Update Summary Spring 2009 Center for Health Statistics Minnesota Department of Health TABLE OF CONTENTS BACKGROUND... 1 PART I: BIRTH-RELATED HEALTH
More informationScreening Asymptomatic Women for Ovarian Cancer: American College of Preventive Medicine Practice Policy Statement
ATTENTION This Policy was reaffirmed by the ACPM Board of Regents on 1/31/2005 and is effective through 1/31/2010. Screening Asymptomatic Women for Ovarian Cancer: American College of Preventive Medicine
More informationCase-Control Studies. Sukon Kanchanaraksa, PhD Johns Hopkins University
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationBREAST CANCER IN THE 21 st CENTURY. The Carolinas Medical Center NorthEast Experience. Garry Schwartz, MD
BREAST CANCER IN THE 21 st CENTURY The Carolinas Medical Center NorthEast Experience Garry Schwartz, MD The American Cancer Society's most recent estimates for breast cancer in the United States for 2009
More informationLow-dose CT Imaging. Edgar Fearnow, M.D. Section Chief, Computed Tomography, Lancaster General Hospital
Lung Cancer Screening with Low-dose CT Imaging Edgar Fearnow, M.D. Section Chief, Computed Tomography, Lancaster General Hospital Despite recent declines in the incidence of lung cancer related to the
More informationAppendices. 2006 Bexar County Community Health Assessment Appendices Appendix A 125
Appendices Appendix A Recent reports suggest that the number of mothers seeking dropped precipitously between 2004 and 2005. Tables 1A and 1B, below, shows information since 1990. The trend has been that
More informationPROTOCOL OF THE RITA DATA QUALITY STUDY
PROTOCOL OF THE RITA DATA QUALITY STUDY INTRODUCTION The RITA project is aimed at estimating the burden of rare malignant tumours in Italy using the population based cancer registries (CRs) data. One of
More informationManagement of Benign Intraductal Solitary Papilloma Diagnosed on Core Needle Biopsy
Ann Surg Oncol (2013) 20:1900 1905 DOI 10.1245/s10434-012-2846-9 ORIGINAL ARTICLE BREAST ONCOLOGY Management of Benign Intraductal Solitary Papilloma Diagnosed on Core Needle Biopsy Ryan E. Swapp, MD 1,
More informationMeasure #112 (NQF 2372): Breast Cancer Screening National Quality Strategy Domain: Effective Clinical Care
Measure #112 (NQF 2372): Breast Cancer Screening National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY DESCRIPTION: Percentage of women 50
More informationLiver Transplantation for Hepatocellular Carcinoma. John P. Roberts, MD Chief, Division of Transplant Service University of California, San Francisco
Liver Transplantation for Hepatocellular Carcinoma John P. Roberts, MD Chief, Division of Transplant Service University of California, San Francisco Hepatocellular Carcinoma HCC is the 5th most common
More informationAre Patients Diagnosed With Breast Cancer Before Age 50 Years Ever Cured? Hermann Brenner and Timo Hakulinen
VOLUME 22 NUMBER 3 FEBRUARY 1 2004 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Are Patients Diagnosed With Breast Cancer Before Age 50 Years Ever Cured? Hermann Brenner and Timo Hakulinen
More informationBreast Cancer: Early Detection
Breast Cancer: Early Detection The importance of finding breast cancer early The goal of screening exams for early breast cancer detection is to find cancers before they start to cause symptoms. Screening
More informationIllinois Insurance Facts Illinois Department of Insurance Coverage for the Diagnosis and Treatment of Breast Conditions
Illinois Insurance Facts Illinois Department of Insurance Coverage for the Diagnosis and Treatment of Breast Conditions Revised May 2015 Note: This information was developed to provide consumers with general
More informationTest Sensitivity in the Computer-Aided Detection of Breast Cancer from Clinical Mammographic Screening: a Meta-analysis
Test Sensitivity in the Computer-Aided Detection of Breast Cancer from Clinical Mammographic Screening: a Meta-analysis Corresponding Author: Jacob Levman 1,2, PhD 1. Institute of Biomedical Engineering
More informationLocal Coverage Determination (LCD): Screening and Diagnostic Mammography (L29328)
Local Coverage Determination (LCD): Screening and Diagnostic Mammography (L29328) Contractor Information Contractor Name First Coast Service Options, Inc. LCD Information Document Information LCD ID L29328
More informationCancer Screening. Robert L. Robinson, MD, MS. Ambulatory Conference SIU School of Medicine Department of Internal Medicine.
Cancer Screening Robert L. Robinson, MD, MS Ambulatory Conference SIU School of Medicine Department of Internal Medicine March 13, 2003 Why screen for cancer? Early diagnosis often has a favorable prognosis
More informationSurgical guidelines for the management of breast cancer
Available online at www.sciencedirect.com EJSO xx (2009) S1eS22 www.ejso.com Guidelines Surgical guidelines for the management of breast cancer Contents Association of Breast Surgery at BASO 2009 Introduction...
More informationColorectal Cancer Screening Behaviors among American Indians in the Midwest
JOURNAL OF HD RP Journal of Health Disparities Research and Practice Volume 4, Number 2, Fall 2010, pp. 35 40 2010 Center for Health Disparities Research School of Community Health Sciences University
More informationTry out the online ROMA calculator available on the Elecsys HE4 page at cobas.com
Try out the online calculator available on the Elecsys HE4 page at cobas.com Download the Roche application for the iphone and the ipad from the App Store. Roche References 1 Huhtinen, K. et al. (29).
More informationWhy I don t recommend endometrial ablation
Why I don t recommend endometrial ablation Endometrial ablation is a major operative procedure that: o Is ineffective because, according to all research, 40% will ultimately still need a hysterectomy,
More informationPathologic Assessment Of The Breast And Axilla After Preoperative Therapy
Pathologic Assessment Of The Breast And Axilla After Preoperative Therapy W. Fraser Symmans, M.D. Associate Professor of Pathology UT M.D. Anderson Cancer Center Pathologic Complete Response (pcr) Proof
More informationEIN. (Endometrial Intraepithelial Neoplasia): Improved Criteria for diagnosing endometrial precancer. Stanley J. Robboy, MD, FCAP,
EIN (Endometrial Intraepithelial Neoplasia): Improved Criteria for diagnosing endometrial precancer Stanley J. Robboy, MD, FCAP, FFPath FRCPI (Hon), FRCPath (UK, Hon) Professor of Pathology, Duke University
More informationSecondary Cancer and Relapse Rates Following Radical Prostatectomy for Prostate-Confined Cancer
Copyright E 2007 Journal of Insurance Medicine J Insur Med 2007;39:242 250 MORTALITY Secondary Cancer and Relapse Rates Following Radical Prostatectomy for Prostate-Confined Cancer David Wesley, MD; Hugh
More informationUnderstanding CA 125 Levels A GUIDE FOR OVARIAN CANCER PATIENTS. foundationforwomenscancer.org
Understanding CA 125 Levels A GUIDE FOR OVARIAN CANCER PATIENTS foundationforwomenscancer.org Contents Introduction...1 CA 125................................... 1 The CA 125 Test...2 The Use of the CA
More informationBreast Cancer: Early Detection
Breast Cancer: Early Detection The importance of finding breast cancer early The goal of screening exams for early breast cancer detection is to find cancers before they start to cause symptoms. Screening
More informationL Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer
Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine and systemic chemotherapy in malignant pleural mesothelioma. A 10-year experience. L Lang-Lazdunski, A Bille, S Marshall, R Lal,
More informationCommon Breast Complaints:
: Palpable mass Abnormal mammogram with normal physical exam Vague thickening or nodularity Nipple Discharge Breast pain Breast infection or inflammation The physician s goal is to determine whether the
More informationBreast Cancer Basic Facts 1. Breast Cancer Occurrence 4. Breast Cancer Risk Factors 11. Breast Cancer Screening 18. Breast Cancer Treatment 23
Breast Cancer Facts & Figures 2013-2014 Contents Breast Cancer Basic Facts 1 Breast Cancer Occurrence 4 Breast Cancer Risk Factors 11 Breast Cancer Screening 18 Breast Cancer Treatment 23 What is the American
More informationCONSOLIDATED GUIDANCE ON STANDARDS FOR THE NHS BREAST SCREENING PROGRAMME
CONSOLIDATED GUIDANCE ON STANDARDS FOR THE NHS BREAST SCREENING PROGRAMME NHSBSP Publication No 60 (Version 2) April 2005 Published by: NHS Cancer Screening Programmes The Manor House 260 Ecclesall Road
More informationDuctal Carcinoma In Situ of the Breast
Melchior de Hondecoeter, 1670. A Golden Eagle Attacking a Menagerie of Birds (detail). From the collection of Dr. and Mrs. Gordon Gilbert of St. Petersburg, FL. Ductal Carcinoma In Situ of the Breast Elisabeth
More informationDiabetes Prevention in Latinos
Diabetes Prevention in Latinos Matthew O Brien, MD, MSc Assistant Professor of Medicine and Public Health Northwestern Feinberg School of Medicine Institute for Public Health and Medicine October 17, 2013
More informationAdditional Double Reading of Screening Mammograms by Radiologic Technologists: Impact on Screening Performance Parameters
ARTICLE Additional Double Reading of Screening Mammograms by Radiologic Technologists: Impact on Screening Performance Parameters Lucien E. M. Duijm, Johanna H. Groenewoud, Jacques Fracheboud, Harry J.
More informationCLINICAL NEGLIGENCE ARTICLE: THE DETECTION & TREATMENT OF BREAST CANCER & CLAIMS FOR LOSS OF LIFE EXPECTANCY IN CLINICAL NEGLIGENCE CASES
CLINICAL NEGLIGENCE ARTICLE: THE DETECTION & TREATMENT OF BREAST CANCER & CLAIMS FOR LOSS OF LIFE EXPECTANCY IN CLINICAL NEGLIGENCE CASES Reports relating to the detection and treatment of breast cancer
More informationPap smears, cytology and CCHC lab work and follow up
Pap smears, cytology and CCHC lab work and follow up What is a Pap Smear? A Pap smear (also known as the Pap test) is a medical procedure in which a sample of cells from a woman's cervix (the end of the
More informationPre test Question 2. Emily D. Babcock, DHSc, PA C, DFAAPA CAPA Annual Conference Palm Springs, California October 4, 2013
Emily D. Babcock, DHSc, PA C, DFAAPA CAPA Annual Conference Palm Springs, California October 4, 2013 Objectives After completion of this presentation, the participant will be able to: Explain the current
More informationMammography. What is Mammography?
Scan for mobile link. Mammography Mammography is a specific type of breast imaging that uses low-dose x-rays to detect cancer early before women experience symptoms when it is most treatable. Tell your
More informationData Analysis, Research Study Design and the IRB
Minding the p-values p and Quartiles: Data Analysis, Research Study Design and the IRB Don Allensworth-Davies, MSc Research Manager, Data Coordinating Center Boston University School of Public Health IRB
More informationChapter 2: Health in Wales and the United Kingdom
Chapter 2: Health in Wales and the United Kingdom This section uses statistics from a range of sources to compare health outcomes in Wales with the remainder of the United Kingdom. Population trends Annual
More informationCXCA-MSP. The next step in cervical cancer prevention! GynTect : Epigenetic biomarkers for reliable cancer diagnostics. www.gbo.
CXCA-MSP The next step in cervical cancer prevention! GynTect : Epigenetic biomarkers for reliable cancer diagnostics www.gbo.com/diagnostics H 3 C NH 2 NH H 3 C 2 N mc N mc N H N O H O The challenge of
More informationBreast Cancer Prevention and Early Detection
Breast Cancer Prevention and Early Detection What is breast cancer Breast cancer is a malignant tumor that starts in the cells of the breast. A malignant tumor is a group of cancer cells that can grow
More informationMedicare Part B. Mammograms - Updated Billing Guide for Screening and Diagnostic Tests
Mammograms - Updated Billing Guide for Screening and Diagnostic Tests This article from Medicare B News Issue 223 dated October 21, 2005 is being updated and reprinted to ensure that the Noridian Administrative
More informationBreast Cancer Screening Clinical Practice Guideline
NATIONAL CLINICAL PRACTICE GUIDELINE Breast Cancer Screening Clinical Practice Guideline This guideline is informational only. It is not intended or designed as a substitute for the reasonable exercise
More informationCompleteness of Physician Billing Claims for Diabetes Prevalence Estimation
Completeness of Physician Billing Claims for Diabetes Prevalence Estimation Lisa M. Lix 1, John Paul Kuwornu 1, George Kephart 2, Khokan Sikdar 3, Hude Quan 4 1 University of Manitoba; 2 Dalhousie University;
More information